[Pulse-dose cyclophosphamide therapy for chronic progressive multiple sclerosis]. 1993

T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
Department of Neurology, Fukushima Medical College.

Although cyclophosphamide pulse therapy has been reported to be beneficial for patients with chronic progressive multiple sclerosis for whom other treatment modalities are not expected to improve outcome, the experience with Japanese patients has not been shown in the literature. The reason appears due, in part, to the small size of this group and to the side effects inherent to such a large dose immunosuppressive regimen. Here, we report on 3 cases with chronic progressive multiple sclerosis who have undergone the pulse-dose cyclophosphamide treatment. The cases included 3 women, two with primary progressive multiple sclerosis (one, the classical form and the other, the spinal cord from). The 3rd case was that of myelitis-optic neuritic form and the total blindness of right eye (left side had been totally blind) was impending despite repeated corticosteroid therapies. The regimen included 600 mg/m2 intravenous cyclophosphamide per day at days 1, 2, 4, 6, 8 and infusion of totally 2,500-3,000 ml of intravenous fluid in order for avoiding hemorrhagic cystitis. The side effects were nausea, anorexia, leucopenia (10-15 days from the end of the course and the lowest value being 1,100/microliters), microscopic hematuria in one case, and alopecia in all. All the patients tolerated the therapy well. Two cases improved to a significant degree and the 3rd case with impending blindness has shown the arrest of progression. However, two of them began progressing again in one- to two-year period and the pulse-dose had to be repeated. These 3 cases have shown neurological improvements or at least arrest of the progression following the therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
January 1987, NITA,
T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
January 2010, Indian journal of dermatology,
T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
August 1987, Archives of neurology,
T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
January 1988, Annals of the New York Academy of Sciences,
T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
February 1998, Italian journal of neurological sciences,
T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
April 1994, Der Nervenarzt,
T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
October 2003, Ryumachi. [Rheumatism],
T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
January 2009, Indian journal of dermatology, venereology and leprology,
T Watanabe, and T Yamamoto, and T Saito, and M Sugano, and T Tsukamoto
December 1999, Multiple sclerosis (Houndmills, Basingstoke, England),
Copied contents to your clipboard!